JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.
Needham Maintains Buy on Symbotic, Raises Price Target to $18
Needham analyst James Ricchiuti maintains Symbotic (NASDAQ:SYM) with a Buy and raises the price target from $17 to $18.